Results 31 to 40 of about 46,143 (249)

Treatment of thrombotic thrombocytopenic purpura

Terapevticheskii arkhiv, 2021
The review discusses approaches to treatment of congenital thrombotic thrombocytopenic purpura (TTP) or Upshaw-Schulman syndrome. In congenital TTP, plasma transfusions are sufficient. Such treatment options as plasma exchange, administration of clotting factor VIII concentrate, recombinant ADAMTS13, are also used.
Gennadii M. Galstyan, Alexei A. Maschan, Elizaveta E. Klebanova, Irina I. Kalinina   +3 more
openaire   +7 more sources

Thrombotic Thrombocytopenic Purpura in Dengue Fever

Acta Medica Indonesiana, 2021
Thrombotic thrombocytopenic purpura is a rare but life threatening medical condition. Early recognition and treatment of thrombotic thrombocytopenic purpura is important especially in patients who do not present with the classic pentad to reduce the ...
Tze Yuan Tee, Rizna Abdul Cader
doaj  

Inherited thrombotic thrombocytopenic purpura

Haematologica, 2009
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia accompanied by variable neurological dysfunction, renal failure and fever.[1][1] Lesions consist of vessel wall thickening (mainly arterioles ...
Miriam Galbusera, Marina Noris, Giuseppe Remuzzi   +2 more
doaj   +4 more sources

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. [PDF]

, 2009
The activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome.
Bõze, Tamás, Cervenak, László, Derzsy, Zoltán, Gombos, Tímea, Hársfalvi, Jolán, Makó, Veronika, Molvarec, Attila, Prohászka, Zoltán, Rigó, János, Udvardy, Miklós László   +9 more
core   +1 more source

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica, 2016
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao, Huy P. Pham, Lance A. Williams, Jenny McDaniel, Rance C. Siniard, Robin G. Lorenz, Marisa B. Marques, X. Long Zheng   +7 more
doaj   +1 more source

Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Blood, 2020
Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation
George Goshua, P. Sinha, J. Hendrickson, C. Tormey, Pavan K Bendapudi, A. Lee   +5 more
semanticscholar   +1 more source

Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Incidences of immune thrombocytopenic purpura occur in 1 in every 1000–10,000 pregnancies accounting for 3% of all thrombocytopenic pregnancies.
Naser Al-Husban, Oqba Al-Kuran
doaj   +1 more source

Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. [PDF]

, 2014
Plasma exchange (PEX) is a life-saving therapeutic procedure in patients with thrombotic thrombocytopaenic purpura (TTP) and other thrombotic microangiopathic anaemias (TMAs). However, it may be associated with significant complications, exacerbating the
Collier, D, Leverett, D, McGuckin, S, Scully, M, Webster, H, Westwood, JP   +5 more
core   +2 more sources

Thrombotic thrombocytopenic purpura

Journal of Thrombosis and Haemostasis, 2005
This overview summarizes the history of thrombotic thrombocytopenic purpura (TTP) from its initial recognition in 1924 as a most often fatal disease to the discovery in 1997 of ADAMTS-13 deficiency as a major risk factor for acute disease manifestation.
J. A. Kremer Hovinga, Bernhard Lämmle, Lorenzo Alberio   +2 more
openaire   +5 more sources

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience

Haematologica, 2012
Background Acquired thrombotic thrombocytopenic purpura is still associated with a 10–20% death rate. It has still not been possible to clearly identify early prognostic factors of death.
Ygal Benhamou, Cyrielle Assié, Pierre-Yves Boelle, Marc Buffet, Rana Grillberger, Sandrine Malot, Alain Wynckel, Claire Presne, Gabriel Choukroun, Pascale Poullin, François Provôt, Didier Gruson, Mohamed Hamidou, Dominique Bordessoule, Jacques Pourrat, Jean-Paul Mira, Véronique Le Guern, Claire Pouteil-Noble, Cédric Daubin, Philippe Vanhille, Eric Rondeau, Jean-Bernard Palcoux, Christiane Mousson, Cécile Vigneau, Guy Bonmarchand, Bertrand Guidet, Lionel Galicier, Elie Azoulay, Hanspeter Rottensteiner, Agnès Veyradier, Paul Coppo   +30 more
doaj   +1 more source